Melody C Carter1, Sarah T Clayton2, Hirsh D Komarow2, Erica H Brittain3, Linda M Scott2, Daly Cantave4, Donna M Gaskins2, Irina Maric5, Dean D Metcalfe2. 1. Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: mcarter@niaid.nih.gov. 2. Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 3. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 4. Department of Nursing, Clinical Center, National Institutes of Health, Bethesda, Md. 5. Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md.
Abstract
BACKGROUND: The management of children with pediatric mastocytosis poses a challenge. This is because there is limited information as to the application of clinical and laboratory findings and bone marrow histopathology as they relate to medical intervention and communication. OBJECTIVE: We sought to examine clinical aspects of pediatric mastocytosis in relationship to serum tryptase levels and bone marrow pathology to provide practical guidance for management. METHODS: Between 1986 and 2012, 105 children were evaluated at the National Institutes of Health. Organomegaly was confirmed by means of ultrasound. Baseline tryptase levels and at least 1 subsequent tryptase measurement was available in 84 and 37 of these children, respectively. Fifty-three children underwent a bone marrow examination. These data were used to examine relationships between clinical findings, tryptase levels, and marrow histopathology. RESULTS: In patients with high tryptase levels and severe mediator symptoms, all with organomegaly had systemic disease, and none without organomegaly had systemic disease. Serum tryptase levels differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categories versus control subjects (P < .0001). Tryptase levels and symptoms decreased over time in most patients, and tryptase levels correlated with bone marrow mast cell burden in patients with systemic mastocytosis (P < .0001). There was a significant relationship between clinical resolution and the percentage decrease in tryptase levels (P = .0014). CONCLUSIONS: The majority of children experienced major or complete disease resolution (57%), whereas the remainder exhibited partial improvement. Organomegaly was a strong indicator of systemic disease. Serum tryptase levels furthered classification and reflected clinicopathologic findings, while sequential tryptase measurements were useful in supplementing clinical judgment as to disease course. Published by Elsevier Inc.
BACKGROUND: The management of children with pediatric mastocytosis poses a challenge. This is because there is limited information as to the application of clinical and laboratory findings and bone marrow histopathology as they relate to medical intervention and communication. OBJECTIVE: We sought to examine clinical aspects of pediatric mastocytosis in relationship to serum tryptase levels and bone marrow pathology to provide practical guidance for management. METHODS: Between 1986 and 2012, 105 children were evaluated at the National Institutes of Health. Organomegaly was confirmed by means of ultrasound. Baseline tryptase levels and at least 1 subsequent tryptase measurement was available in 84 and 37 of these children, respectively. Fifty-three children underwent a bone marrow examination. These data were used to examine relationships between clinical findings, tryptase levels, and marrow histopathology. RESULTS: In patients with high tryptase levels and severe mediator symptoms, all with organomegaly had systemic disease, and none without organomegaly had systemic disease. Serum tryptase levels differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categories versus control subjects (P < .0001). Tryptase levels and symptoms decreased over time in most patients, and tryptase levels correlated with bone marrow mast cell burden in patients with systemic mastocytosis (P < .0001). There was a significant relationship between clinical resolution and the percentage decrease in tryptase levels (P = .0014). CONCLUSIONS: The majority of children experienced major or complete disease resolution (57%), whereas the remainder exhibited partial improvement. Organomegaly was a strong indicator of systemic disease. Serum tryptase levels furthered classification and reflected clinicopathologic findings, while sequential tryptase measurements were useful in supplementing clinical judgment as to disease course. Published by Elsevier Inc.
Authors: G Akoglu; G Erkin; B Cakir; G Boztepe; S Sahin; A Karaduman; N Atakan; T Akan; F Kolemen Journal: J Eur Acad Dermatol Venereol Date: 2006-09 Impact factor: 6.166
Authors: D González de Olano; B de la Hoz Caballer; R Núñez López; L Sánchez Muñoz; M Cuevas Agustín; M C Diéguez; I Alvarez Twose; M C Castells; L Escribano Mora Journal: Clin Exp Allergy Date: 2007-10 Impact factor: 5.018
Authors: Irina Maric; Jamie Robyn; Dean D Metcalfe; Michael P Fay; Melody Carter; Todd Wilson; Weiming Fu; Jennifer Stoddard; Linda Scott; Marilyn Hartsell; Arnold Kirshenbaum; Cem Akin; Thomas B Nutman; Pierre Noel; Amy D Klion Journal: J Allergy Clin Immunol Date: 2007-07-12 Impact factor: 10.793
Authors: Aubri M Waters; Hyun J Park; Andrew L Weskamp; Allyson Mateja; Megan E Kachur; Jonathan J Lyons; Benjamin J Rosen; Nathan A Boggs Journal: J Allergy Clin Immunol Pract Date: 2022-01-12
Authors: Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin Journal: J Allergy Clin Immunol Date: 2021-03-11 Impact factor: 14.290
Authors: Justyna Czarny; Monika Żuk; Anton Zawrocki; Katarzyna Plata-Nazar; Wojciech Biernat; Marek Niedoszytko; Hanna Ługowska-Umer; Bogusław Nedoszytko; Bartosz Wasąg; Roman J Nowicki; Magdalena Lange Journal: Acta Derm Venereol Date: 2020-05-28 Impact factor: 3.875
Authors: Magdalena Lange; Karin Hartmann; Melody C Carter; Frank Siebenhaar; Ivan Alvarez-Twose; Inés Torrado; Knut Brockow; Joanna Renke; Ninela Irga-Jaworska; Katarzyna Plata-Nazar; Hanna Ługowska-Umer; Justyna Czarny; Anna Belloni Fortina; Francesca Caroppo; Roman J Nowicki; Bogusław Nedoszytko; Marek Niedoszytko; Peter Valent Journal: Int J Mol Sci Date: 2021-03-04 Impact factor: 5.923